Zasocitinib: A Promising Oral Solution for Plaque Psoriasis

Takeda’s oral TYK2 inhibitor zasocitinib demonstrated robust skin clearance in pivotal Phase 3 trials, according to the company’s topline press release; links to the underlying study report or registry should be added when available.

The randomized, multicenter studies enrolled adults with moderate-to-severe plaque psoriasis and compared once-daily oral zasocitinib with placebo and an active comparator. Co-primary endpoints were sPGA 0/1 and PASI 75 at week 16, aligning the trials with standard clinical benchmarks for clearance and speed of response.

Topline efficacy was notable: more than 50% of treated patients achieved PASI 90 by week 16 (press release; sample size and analysis population not specified), PASI 75 responses appeared as early as week 4, and sPGA 0/1 targets were met at the prespecified timepoint—findings that indicate rapid and substantial skin improvement for many participants.

Safety results reported no new signals. The most common adverse events were upper respiratory tract infections, nasopharyngitis and acne, and overall tolerability was consistent with prior studies reported for this mechanism—supporting established monitoring approaches and suggesting suitability for patients who prefer an oral option.

Clinically and commercially, an oral TYK2 inhibitor such as zasocitinib could rival injectable biologics by combining convenience with high rates of skin clearance, with potential downstream effects on prescribing patterns and payer discussions. Takeda plans regulatory submissions beginning in fiscal year 2026; approval timing and reimbursement pathways remain to be determined.